Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more
Calman A. MacLennan

Contact information


calman.maclennan@ndm.ox.ac.uk


Raquel Gomez-Menor Munoz
raquel.gomez-menor@ndm.ox.ac.uk


https://www.jenner.ac.uk/

Calman A. MacLennan

BM, BCh, DPhil, FHEA, FRCP, FRCPath

Professor of Vaccine Immunology (University of Birmingham)

  • Jenner Investigator and Group Leader - Gonococcal Vaccine Project, Jenner Institute
  • Director of BactiVac, the Bacterial Vaccines Network, Institute of Immunology and Immunotherapy, University of Birmingham, UK
  • Consultant Immunologist, Oxford University Hospitals NHS Foundation Trust, UK
  • Senior Program Officer, Bacterial Vaccines, Global Health, Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation, Seattle, US

Vaccinologist, Immunologist & Clinician Scientist focused on bacterial infections and AMR

Calman MacLennan is a clinician scientist, vaccinologist and immunologist who joined the Jenner Institute in 2015. For the past 25 years, his career has focused on understanding mechanisms of immunological of protection against bacterial infections of global health significance and antimicrobial resistance (AMR) concern. This knowledge has then been applied to the development of protective vaccines.

With experience of vaccine development in academia and industry, he has been involved in the development of several bacterial vaccines including one licensed vaccine against typhoid and other vaccines currently in clinical trials.

He leads the Gonococcal Vaccine Project which is using native Outer Membrane Vesicle (nOMV) technology to develop a candidate vaccine against Neisseria gonorrhoeae, the causative agent of gonorrhoea. Gonorrhoea infects 82.4 million people each year and is rapidly becoming resistant to all known antibiotics.

Professor MacLennan is the founder and director of BactiVac, the Bacterial Vaccines Network, a worldwide network based out of the University of Birmingham with a mission to accelerate the development of vaccines against bacterial pathogens as a countermeasure to AMR. He is a Consultant Immunologist at the Oxford University Hospitals NHS Foundation Trust.

Key publications

More publications